HAMBURG, Germany, Aug. 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug discovery service company RSIPL for EUR 2.8 million in cash, a portion of which includes a potential earn-out.
